Numerous studies have assessed the association between smoking and subsequent risks of mortality and morbidity, but the effect estimates varied substantially across studies. 7 A previous meta-analysis included 46 studies published before Background-The prevalence of smoking in diabetic patients remains high, and reliable quantification of the excess mortality and morbidity risks associated with smoking is important for diabetes management. We performed a systematic review and meta-analysis of prospective cohort studies to evaluate the relation of active smoking with risk of total mortality and cardiovascular events among diabetic patients. Methods and Results-We searched Medline and Embase databases through May 2015, and multivariate-adjusted relative risks were pooled by using random-effects models. A total of 89 cohort studies were included. The pooled adjusted relative risk (95% confidence interval) associated with smoking was 1.55 (1.46-1.64) for total mortality (48 studies with 1 132 700 participants and 109 966 deaths), and 1.49 (1.29-1.71) for cardiovascular mortality (13 studies with 37 550 participants and 3163 deaths). The pooled relative risk (95% confidence interval) was 1.44 (1.34-1.54) for total cardiovascular disease (16 studies), 1.51 (1.41-1.62) for coronary heart disease (21 studies), 1.54 (1.41-1.69) for stroke (15 studies), 2.15 (1.62-2.85) for peripheral arterial disease (3 studies), and 1.43 (1.19-1.72) for heart failure (4 studies).
D
iabetes mellitus has become a global public health crisis, and the International Diabetes Federation estimated that 387 million adults were affected by diabetes mellitus in 2014 worldwide, and the number was predicted to continue to rise at an alarming rate and reach 592 million by 2035. 1 Furthermore, people with diabetes mellitus have an increased risk of developing a number of serious health problems, including macrovascular (cardiovascular disease, CVD) and microvascular (retinopathy, nephropathy and neuropathy) complications. 2 It has also been widely acknowledged that smoking is a leading risk factor for diabetes mellitus, 3, 4 CVD, 4 and total mortality 4 in the general population. Smoking cessation is a major target for diabetes treatment 2 ; however, many patients continue to smoke even after a diagnosis of diabetes mellitus, 5 and the success rate of smoking cessation interventions among diabetic patients is not high, with some studies reporting it to be ≈20%. 6 Therefore, evaluation of the additional hazards associated with active smoking and the potential benefits of smoking cessation among diabetic patients will provide direct evidence for the clinical practice and behavior changes.
2011 that focused on total mortality and cardiovascular outcomes, and suggested that smoking was a modifiable risk factor for adverse outcomes among diabetic patients. 7 However, the meta-analysis omitted several important articles that were eligible. Since 2011, many more studies have been published that allow more detailed analysis of the association in different populations and subgroups. Therefore, we conducted a comprehensive systematic review and meta-analysis of prospective cohort studies to describe the association between smoking and risk of total mortality and cardiovascular outcomes among diabetic patients.
Methods Data Sources, Search Strategy, and Eligibility Criteria
We first searched the literature of Medline and Embase in April 2014 for studies describing the association between cigarette smoking and any adverse outcomes among diabetic patients. To make sure our study was based on up-to-date results, we further updated the literature search of Medline on May 3, 2015 . In addition, we searched the reference lists of all identified relevant publications and relevant reviews. 6, 7 Only articles published in the English language were considered. The search focused on 3 themes of Medical Subject Heading terms and related exploded versions: smoking or cigarette, diabetes mellitus or glucose metabolism irregularity, and studies with a prospective design. The 3 themes were combined by using the Boolean operator "and." The detailed search strategies are shown in the online-only Data Supplement.
Study Selection
Two investigators (Ms Wang and Mr Talaei) independently assessed literature eligibility; discrepancies were resolved by consensus or by consulting with the third investigator (Dr Pan). Articles were considered for inclusion in the systematic review if: (1) the authors reported data from an original, peer-reviewed study (ie, not review articles or meeting abstracts); (2) the study was a cohort study consisting of noninstitutionalized adults (>18 years of age) with diabetes mellitus (including type 1 or type 2 diabetes mellitus); and (3) the authors reported risk estimates of total mortality or cardiovascular outcomes in diabetic participants by baseline smoking status. We included different comparisons by smoking status (comparing current with never smokers, current with noncurrent smokers, former with never smokers, and ever with never smokers). Given the large number of included studies, and to reduce the influence from studies of limited statistical power, we decided to exclude studies with a total sample size of <100 participants, or <50 total disease outcomes. Studies reporting crude associations without any adjustment were also excluded. A sensitivity analysis of including those studies in the meta-analysis did not materially alter the results (data not shown). In the case of multiple publications, we included the articles with the longest follow-up years or the largest number of incident cases. We identified articles eligible for further review by performing an initial screen of identified titles or abstracts, followed by a full-text review.
Data Extraction
We extracted the following information about the studies: study characteristics (study name, authors, publication year, journal, study location, follow-up years, and number of participants), participants' characteristics (mean age or age range, sex, ethnicity), smoking status (never, past, and current), disease outcomes (assessed by self-reports, death certificates, medical records, or clinical examinations), and analysis strategy (statistical models, covariates included in the models). If the information was unavailable or not clear from a published report, we collected relevant data by corresponding with the authors. Quality assessment was performed with consideration of the following aspects 8 : validity of outcome measurements, exclusion of outcome at baseline, selection of nonexposure group, follow-up years, confounding adjustment, and generalizability to other populations. Smoking status was self-reported in all the studies, and most studies did not report information of response rate and follow-up rate.
Data Synthesis and Analysis
The relative risk (RR) was used as the common measure of association across studies, and the hazard ratio or rate ratio was considered equivalent to RR, 9 whereas the odds ratio (OR) was converted to RR by the formula RR=OR/[(1-P o )+(P o ×OR)], in which P o is the incidence of the outcome of interest in the nonexposed group. 10 Forest plots were produced to visually assess the RRs and corresponding 95% confidence intervals (CIs) across studies. Heterogeneity across studies was evaluated by the Cochrane Q statistic (significance level of P<0.10) and the I 2 statistic (ranges from 0% to 100% with lower values representing less heterogeneity). 11 The RRs were pooled by using the DerSimonian and Laird 12 inverse variance-weighted random-effects models. The possibility of publication bias was evaluated using the Egger test and visual inspection of a funnel plot. 13 The Duval and Tweedie 14 nonparametric trim-and-fill method was used to further assess the possible effect of publication bias. Moreover, stratified analyses and sensitivity analyses were performed to evaluate the influences of selected study and participant characteristics on the results. Finally, we omitted 1 study at each time to test the robustness of the results and the influence of individual study on the heterogeneity. The analyses were performed with Stata version 11.2 (StataCorp, College Station, TX).
We calculated absolute risk differences associated with smoking by multiplying the background incidence rate of disease outcomes in diabetic populations with estimated (RR−1). Population attributable fraction (PAF) was calculated based on the following equation: PAF=100%×P e (RR-1)/(P e [RR-1]+1), where P e is the prevalence of the smoking in the population and RR was derived from this meta-analysis.
Results

Literature Search
The search strategy identified 12 598 unique citations. After the first round of screening based on titles and abstracts with the aforementioned criteria, 1066 articles remained for further evaluation. After detailed examination, 996 articles were excluded for reasons shown in Figure 1 . Another 15 studies were retrieved from the reference lists of relevant articles and reviews, and 4 studies were from the full publications of meeting abstracts (see online-only Data Supplement). In total, 89 articles were included, and the full list of the publications is shown in the online-only Data Supplement.
Among these 89 articles, 48 studies specifically reported results on total mortality, 13 studies on cardiovascular mortality, 16 studies on total CVD, 21 studies on coronary heart disease (CHD), 15 studies on stroke, 3 studies on peripheral arterial disease and 4 studies on heart failure. Some studies reported multiple outcomes. The characteristics of the included studies are shown in Tables I and II in the onlineonly Data Supplement. without baseline CVD, and thus 50 reports from 48 studies were included with a total of 1 132 700 participants and 109 966 deaths. Of the 48 studies, most were conducted in European countries (n=24) and the United States (n=14). Most studies were performed in T2D patients, whereas 5 studies were performed in T1D patients, and 4 studies in both types. Most studies included both men and women, whereas 3 studies were conducted exclusively in men and 1 was conducted exclusively in women. The prevalence of current smoking and the follow-up years varied across studies.
The majority of studies reported a positive association (ie, RR >1.00), only 2 studies reported RR <1.00 but not statistically significant. A high heterogeneity was detected (I 2 =77.6%; P<0.001), and the RR (95% CI) from random-effects model was 1.55 (1.46-1.64; Figure 2) . A sensitivity analysis of omitting 1 study in each turn showed no substantial change on the results with pooled RRs ranging from 1.53 to 1.57 (data not shown). The RR (95% CI) remained significant in T1D patients (1.77; 1.52-2.07; 6 reports) and T2D patients (1.53; 1.44-1.63; 41 reports), and in many subgroups, as well (Table  III in the online-only Data Supplement). The results were similar when comparing current smoking with never (RR=1. 62) or noncurrent (RR=1.53) smoking, or comparing ever with never smoking (RR=1.51; Table III in the online-only Data Supplement). Furthermore, 13 studies reported results for former in comparison with never smoking, and the pooled RR (95% CI) was 1.19 (1.11-1.28; Table III in the online-only  Data Supplement) .
For cardiovascular mortality, 1 study 17 reported results separately for types of diabetes mellitus and sex, thus a total of 16 reports from 13 studies were combined with 37 550 participants and 3163 CVD deaths (Table I in the online-only Data Supplement). Most studies were conducted in both sexes (n=11), and in European countries (n=7). The pooled RR (95% CI) was 1.49 (1.29-1.71; I 2 =26.5%; P for heterogeneity=0.16; Figure 3 ). The association remained significant in studies among T1D patients (1.91; 1.29-2.85; 3 reports) and T2D patients (1.44; 1.24-1.68; 13 reports), and many subgroups (Table III in 
Smoking and Risk of Cardiovascular Events Among Diabetic Patients
Characteristics of the studies reporting smoking and cardiovascular outcomes are shown in Table II were found with 1 028 982 participants and 94 929 outcomes (1 study 18 did not report the number of CVD cases). Most studies were conducted in European countries (n=8), and the others were from the United States (n=4), Australia and New Zealand (n=2), China (n=1), and international collaboration (n=1). All studies were conducted in T2D patients, with the exception of 1 in T1D patients. The pooled RR (95% CI) was 1.44 (1.34-1.54; I 2 =73.9%; P for heterogeneity <0.001; Figure 4) . A sensitivity analysis of omitting 1 study in each turn showed no substantial change on the results with pooled RRs ranging from 1.39 to 1.47 (data not shown).
For CHD risk, 26 reports from 21 studies were found with 1 009 457 participants and 38 752 outcomes (Table II in the online-only Data Supplement). Again, most studies were conducted in the United States (n=9) and European countries (n=8), and the others were in New Zealand (n=1), China (n=1), Japan (n=1), and international collaboration (n=1). Seventeen studies were done in T2D patients, 3 in T1D patients, and 1 in both types. The pooled RR (95% CI) was 1.51 (1.41-1.62; I 2 =60.8%; P for heterogeneity <0.001; Figure 4 18 did not report the number of stroke cases; Table II in the online-only Data Supplement). Again, most studies were conducted in European countries (n=8) and the United States (n=4), and the others were in China (n=1) and international collaboration (n=2). All studies were done in T2D patients, with the exception of 1 study in both types. The pooled RR (95% CI) was 1.54 (1.41-1.69; I 2 =70.9%; P for heterogeneity <0.001; Figure 4 ). A sensitivity analysis of omitting 1 study in each turn showed no substantial change on the results with pooled RRs ranging from 1.47 to 1.62 (data not shown).
The significant relations of smoking with CVD, CHD, and stroke among diabetic patients were observed in most subgroups (Table IV in the online-only Data Supplement). In comparison with never smoking, former smoking was associated with a moderately elevated risk of CVD (RR, 1.09; 95% CI, 1.05-1.13; 7 reports) and CHD (RR, 1.14; 95% CI, 1.00-1.30; 13 reports), but not significant for stroke (RR, 1.04; 95% CI, 0.87-1.23; 9 reports).
As for other cardiovascular outcomes, we also found significant relations of smoking with peripheral arterial disease (RR, 2.15; 95% CI, 1.63-2.85; I 2 =33.6%; P for heterogeneity=0.22; 3 reports), and heart failure (RR, 1.43; 95% CI, 1.19-1.72; I 2 =93.8%; P for heterogeneity<0.001; 5 reports), and all the associations in individual studies were significant ( Figure I in the online-only Data Supplement).
Analysis of Publication Bias
Visual inspection of the funnel plot revealed moderate asymmetry for total mortality ( Figure IIA in the online-only Data Supplement), and the Egger test was not significant (P=0.11). A sensitivity analysis using the trim-and-fill method was performed with 14 additional imputed studies, which produced a symmetrical funnel plot ( Figure IIB in 
Absolute Risk Difference and PAF
Using the data from the World Health Organization Multinational Study of Vascular Disease in Diabetes, 17 we estimated that the absolute risk difference associated with smoking for total mortality was 117 for T2D and 286 for T1D per 10 000 patients per year worldwide. According to the global prevalence of daily smoking from a recent publication (assuming that the smoking prevalence was similar between diabetic patients and the general population), 22 and using the risk estimates from our meta-analysis and global estimates of deaths from diabetes mellitus, 1 we estimated that 14.6% of total deaths in men and 3.3% in women (≈438 000 deaths annually) were attributable to active smoking among diabetic patients worldwide. The corresponding PAFs for other outcomes (CVD mortality, total CVD, CHD, and stroke) ranged from 12.0% to 14.4% in men and 2.7% to 3.3% in women (Table V in the online-only Data Supplement). The PAF calculations should vary in diabetic populations with different smoking prevalence and risk estimates for disease outcomes, and we used the populations in the United States, United Kingdom, and China as examples in Table V in the online-only Data Supplement. For example, the PAFs were much higher in Chinese men but substantially lower in Chinese women. The PAFs were similar in men and women among US and UK populations where smoking was prevalent in both sexes.
Discussion
With the use of data from 89 prospective studies, our metaanalysis demonstrates that active smoking is prospectively associated with ≈50% increased risk of total mortality and cardiovascular events. Furthermore, the associations persisted across most subgroups stratified by various study and participant characteristics. In addition, although the former smokers still had higher risks of total mortality and CVD than never smokers, the increased risks were much lower than the risks in current smokers, suggesting the substantial benefits of smoking cessation among diabetic patients.
Our results are consistent with a previous meta-analysis of 46 studies published before 2011 regarding total mortality and cardiovascular outcomes. 7 However, that meta-analysis missed many important articles. In particular, the authors missed 6 eligible studies [23] [24] [25] [26] [27] [28] in the analysis of total mortality that were published before 2011. Our current meta-analysis included those studies together with many newly published articles (particularly some recent large studies 16, 29, 30 ), thus providing the most accurate and comprehensive estimates of smokingrelated adverse health outcomes among diabetic patients. We included almost double the number of studies and 10-fold more study participants. For example, our meta-analysis of total mortality included 48 studies with 1 132 700 participants November 10, 2015 and 109 966 deaths, whereas the articles by Qin et al 7 only included 27 studies with 100 089 participants and 13 046 deaths. Finally, we also summarized the results for peripheral arterial disease and heart failure in our meta-analysis.
Given the consistency of the results for various outcomes in populations with different characteristics, our findings provide strong evidence that smoking is associated with adverse health consequences among diabetic patients. Similar to studies in the general population that have indicated a causal link between smoking and various disease outcomes (diabetes mellitus, CVD, and mortality), 4 the observed associations among diabetic patients are likely to be causal as well. We observed the positive associations in most subgroups for various outcomes. Although the point estimates may vary in different subgroups, the 95% CIs largely overlapped and the meta-regression analyses did not reveal significant differences between groups. The number of studies in some subgroups was small, thus making the risk estimates unstable. For example, studies in T1D patients and Asian populations are still limited. Furthermore, fewer studies are available for the doseresponse analysis, and analysis of other cardiovascular events, like heart failure.
Smoking remains a major public health threat globally despite large reductions in prevalence over the past several decades. 22 Among diabetic patients, the prevalence of current smoking varied substantially in different studies as shown in our meta-analysis (Tables I and II in the online-only Data Supplement). A previous study in US representative samples found that nearly one-fifth of diabetic patients were still current smokers. 5 Furthermore, the prevalence of current smoking among young adults (18-39 years) with diabetes mellitus was even higher in comparison with nondiabetic individuals (37.0% versus 30.4%). 5 Therefore, smoking cessation remains a major treatment target for diabetic patients. 2 There might be a potential concern for diabetic patients who are motivated to quit smoking because smoking cessation can result in shortterm weight gain, 31 deterioration in glycemic control, 32 and worsening of some diabetic symptoms. 6 However, our current meta-analysis clearly showed that former smokers had relatively lower risk estimates than current smokers. Several studies have consistently reported attenuated risks with longer duration of smoking cessation, 18, 23, 33 which are consistent with the findings in general populations regarding the longterm benefits of smoking cessation on health outcomes. 34, 35 Furthermore, studies in the Framingham Offspring Study 36 and the Women's Health Initiative 37 showed that the recent smoking quitters had similar incidence rates of CVD/CHD events in comparison with the never smokers, and weight gain did not modify the association. Therefore, the current evidence supports a net cardiovascular benefit of smoking cessation among diabetic patients, despite significant short-term weight gain associated with smoking cessation.
We estimated that 14.6% of total deaths in men and 3.3% in women were attributable to smoking among diabetic patients worldwide. These numbers might be underestimated for several reasons. First, we used the age-standardized prevalence of daily smoking in adults >15 years of age, 22 but the prevalence could be higher in middle-aged population 22 when diabetes mellitus is diagnosed. Second, we used the daily smoking prevalence, 22 and the PAFs would be higher if we used the current smoking prevalence from the World Health Organization database. 38 Nevertheless, our findings confirm that smoking is still a leading avoidable cause of morbidity and mortality among diabetic patients, particularly in men. Our results are also comparable to the recent World Health Organization report, 39 where globally 16% of deaths in men and 7% in women were attributable to smoking in the general population. Our point estimates of the increased risks of mortality and CVD associated with smoking among diabetic patients are slightly lower than in the general population. 4 Given the much higher mortality and morbidity rate in diabetic patients in comparison with the general population, the absolute numbers of excess mortality and morbidity cases attributable to smoking are considerable.
Several limitations of this meta-analysis should be acknowledged. First, we found a significant heterogeneity across studies for some outcomes, which may result from differences in study designs, sample sizes, analysis strategies, and participants' characteristics. Although moderate to high heterogeneities still remained in many subgroups, the pooled RRs showed consistent positive associations in most subgroups. Second, the funnel plot indicated a possible publication bias for total mortality and total CVD; however, the trim-and-fill sensitivity analysis did not materially change the results, and the asymmetry of a funnel plot does not necessarily imply publication bias. 40 Third, the meta-analysis was limited to English publications, and the possibility of unpublished reports was not yet identified. The literature screening and data extraction were conducted independently by 2 investigators, and, thus, selection bias was unlikely. Fourth, the definition of smoking varied across studies, but our analysis found similar results of different comparison groups (ie, current with never smoking, ever with never smoking, and current with noncurrent smoking) for all health outcomes. In addition, the associations were presented in different forms (OR, hazard ratio, RR, etc), and RR was used as the common measure of association in this meta-analysis. The summary results might be influenced by the conversion of other measures to RR, but such influence, if any, is likely to be small because only a few studies reported ORs. Moreover, despite strong associations, residual confounding is still possible given that many studies did not adjust for lifestyle factors in their models. Smoking is commonly related to other unhealthy lifestyle factors (eg, unhealthy diet, excessive alcohol use, and physical inactivity) 41, 42 and depression and stress, 43, 44 which are also risk factors for poor health outcomes in diabetic patients. Finally, more studies are needed to determine the magnitude of the associations in certain populations such as Asians and T1D patients.
Conclusions
In conclusion, this meta-analysis provides compelling evidence that smoking is a significant modifiable factor for adverse health consequences in diabetic patients. Given the increasing prevalence of diabetes mellitus and the remaining high prevalence of smoking in many countries, the observed associations between smoking and disease outcomes among diabetic patients have significant clinical and public health by guest on May 24, 2017 http://circ.ahajournals.org/ Downloaded from importance. Our study supports the routine and thorough assessment of tobacco use in diabetic patients, and the inclusion of the prevention and cessation of tobacco use as an important component of clinical diabetes care. More studies are needed to examine the efficacy and effectiveness of smoking cessation interventions to reduce the burden of excess morbidity and mortality associated with smoking among diabetic patients. November 10, 2015 30 
CLINICAL PERSPECTIvE
The prevalence of smoking in diabetic patients remains high, and reliable quantification of the excess mortality and morbidity risks associated with smoking is important for diabetes management. In this meta-analysis of 89 prospective cohort studies, we reported that active smoking was prospectively associated with ≈50% increased risk of total mortality and cardiovascular disease among diabetic patients. More importantly, although the former smokers still had higher risks of total mortality and cardiovascular disease in comparison with never smokers, the increased risks were much lower than the risks in current smokers, suggesting the substantial benefits of smoking cessation among diabetic patients. Despite the guidelines and recommendations of smoking cessation for diabetic patients, the success rate remains low, and there are multiple barriers for the implementation of the guidelines. Our quantitative estimation of the hazards associated with smoking in diabetic patients will help the clinicians and patients understand the risk of continuous smoking, and the benefits of quitting smoking, as well. The findings call for more intensive and effective tobacco control and smoking cessation strategies to reduce the cardiovascular disease burden caused by smoking in diabetic patients. Practicing clinicians are advised to discuss with the patients the potential options for smoking cessation, to weigh the benefits and risks of available therapies, and to develop and monitor specific treatment plans tailored to individual patient needs. More information and support should be given to help patients successfully quit smoking and gain the long-term benefits of smoking cessation.
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Online Supplemental Material
The following materials are included in the Online Supplemental Material.
1. Search strategies in PubMed and EMBASE.
2. List of papers that were included in the meta-analysis but were not found from the search of Pubmed and EMBASE 3. Supplemental Tables 1-5. 4. Supplemental Figures 1-2 .
5. List of references that were included in the meta-analysis The following studies were included using the full text of the meeting abstracts:
Supplemental
Supplemental 50 ‡ The study quality scored from 0 to 9, with higher score indicating higher quality. The study quality scored from 0 to 9, with higher score indicating higher quality. Table 5 
Figure legend
The summary estimates were obtained using a random-effects model. The data markers indicate the adjusted relative risks (RRs) comparing smoking to no smoking. The size of the data markers indicates the weight of the study, which is the inverse variance of the effect estimate. The diamond data markers indicate the pooled RRs. CI indicates confidence interval. 
Supplemental Figure 2. Funnel Plots for (A) Detection of Publication Bias and (B) Trim-and-Fill Correction for Publication Bias for Total Mortality
Figure legends:
The pseudo 95% confidence interval (CI) is computed as part of the analysis that produces the funnel plot, and corresponding to the expected 95% CI for a given standard error (SE). RR indicates relative risk.
